{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T08:33:15Z","timestamp":1779179595387,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,9,28]],"date-time":"2011-09-28T00:00:00Z","timestamp":1317168000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1007\/s00415-011-6251-2","type":"journal-article","created":{"date-parts":[[2011,9,27]],"date-time":"2011-09-27T19:57:22Z","timestamp":1317153442000},"page":"712-719","source":"Crossref","is-referenced-by-count":19,"title":["Difference in chronological changes of outcome measures between untreated and placebo-treated patients of spinal and bulbar muscular atrophy"],"prefix":"10.1007","volume":"259","author":[{"given":"Atsushi","family":"Hashizume","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahisa","family":"Katsuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruhiko","family":"Banno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"Suga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiaki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gen","family":"Sobue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,9,28]]},"reference":[{"key":"6251_CR1","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1212\/WNL.18.7.671","volume":"18","author":"WR Kennedy","year":"1968","unstructured":"Kennedy WR, Alter M, Sung JH (1968) Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology 18:671\u2013680","journal-title":"Neurology"},{"key":"6251_CR2","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1001\/archneur.59.12.1921","volume":"59","author":"AD Sperfeld","year":"2002","unstructured":"Sperfeld AD, Karitzky J, Brummer D et al (2002) X-linked bulbospinal neuronopathy: Kennedy disease. Arch Neurol 59:1921\u20131926","journal-title":"Arch Neurol"},{"issue":"Pt 1","key":"6251_CR3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/brain\/112.1.209","volume":"112","author":"G Sobue","year":"1989","unstructured":"Sobue G, Hashizume Y, Mukai E, Hirayama M, Mitsuma T, Takahashi A (1989) X-linked recessive bulbospinal neuronopathy. A clinicopathological study. Brain 112(Pt 1):209\u2013232","journal-title":"Brain"},{"issue":"Pt 6","key":"6251_CR4","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1093\/brain\/awl096","volume":"129","author":"N Atsuta","year":"2006","unstructured":"Atsuta N, Watanabe H, Ito M et al (2006) Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients. Brain 129(Pt 6):1446\u20131455","journal-title":"Brain"},{"key":"6251_CR5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/352077a0","volume":"352","author":"AR La Spada","year":"1991","unstructured":"La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH (1991) Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352:77\u201379","journal-title":"Nature"},{"key":"6251_CR6","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1023\/A:1005344403603","volume":"20","author":"KH Fischbeck","year":"1997","unstructured":"Fischbeck KH (1997) Kennedy disease. J Inherit Metab Dis 20:152\u2013158","journal-title":"J Inherit Metab Dis"},{"key":"6251_CR7","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nrg2748","volume":"11","author":"AR La Spada","year":"2010","unstructured":"La Spada AR, Taylor JP (2010) Repeat expansion disease: progress and puzzles in disease pathogenesis. Nat Rev Genet 11:247\u2013258","journal-title":"Nat Rev Genet"},{"key":"6251_CR8","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/0022-510X(93)90157-T","volume":"117","author":"G Sobue","year":"1993","unstructured":"Sobue G, Doyu M, Kachi T et al (1993) Subclinical phenotypic expressions in heterozygous females of X-linked recessive bulbospinal neuronopathy. J Neurol Sci 117:74\u201378","journal-title":"J Neurol Sci"},{"key":"6251_CR9","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1212\/WNL.59.5.770","volume":"59","author":"BJ Schmidt","year":"2002","unstructured":"Schmidt BJ, Greenberg CR, Allingham-Hawkins DJ, Spriggs EL (2002) Expression of X-linked bulbospinal muscular atrophy (Kennedy disease) in two homozygous women. Neurology 59:770\u2013772","journal-title":"Neurology"},{"key":"6251_CR10","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0896-6273(02)00834-6","volume":"35","author":"M Katsuno","year":"2002","unstructured":"Katsuno M, Adachi H, Kume A et al (2002) Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 35:843\u2013854","journal-title":"Neuron"},{"key":"6251_CR11","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/nm878","volume":"9","author":"M Katsuno","year":"2003","unstructured":"Katsuno M, Adachi H, Doyu M et al (2003) Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat Med 9:768\u2013773","journal-title":"Nat Med"},{"key":"6251_CR12","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0896-6273(02)00875-9","volume":"35","author":"K Takeyama","year":"2002","unstructured":"Takeyama K, Ito S, Yamamoto A et al (2002) Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron 35:855\u2013864","journal-title":"Neuron"},{"key":"6251_CR13","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1523\/JNEUROSCI.0808-04.2004","volume":"24","author":"ES Chevalier-Larsen","year":"2004","unstructured":"Chevalier-Larsen ES, O\u2019Brien CJ, Wang H et al (2004) Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy. J Neurosci 24:4778\u20134786","journal-title":"J Neurosci"},{"key":"6251_CR14","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/ana.20735","volume":"59","author":"H Banno","year":"2006","unstructured":"Banno H, Adachi H, Katsuno M et al (2006) Mutant androgen receptor accumulation in spinal and bulbar muscular atrophy scrotal skin: a pathogenic marker. Ann Neurol 59:520\u2013526","journal-title":"Ann Neurol"},{"key":"6251_CR15","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/ana.21540","volume":"65","author":"H Banno","year":"2009","unstructured":"Banno H, Katsuno M, Suzuki K et al (2009) Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Ann Neurol 65:140\u2013150","journal-title":"Ann Neurol"},{"key":"6251_CR16","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S1474-4422(10)70182-4","volume":"9","author":"M Katsuno","year":"2010","unstructured":"Katsuno M, Banno H, Suzuki K et al (2010) Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 9:875\u2013884","journal-title":"Lancet Neurol"},{"key":"6251_CR17","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200105243442106","volume":"344","author":"A Hr\u00f3bjartsson","year":"2001","unstructured":"Hr\u00f3bjartsson A, G\u00f8tzsche PC (2001) Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 344:1594\u20131602","journal-title":"N Engl J Med"},{"key":"6251_CR18","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1212\/01.wnl.0000324635.49971.3d","volume":"71","author":"NJ Diederich","year":"2008","unstructured":"Diederich NJ, Goetz CG (2008) The placebo treatments in neurosciences: new insights from clinical and neuroimaging studies. Neurology 71:677\u2013684","journal-title":"Neurology"},{"key":"6251_CR19","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/archneur.1996.00550020045014","volume":"53","author":"ALS The","year":"1996","unstructured":"The ALS (1996) CNTF treatment study (ACTS) phase I-II study group. The amyotrophic lateral sclerosis functional rating scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. Arch Neurol 53:141\u2013147","journal-title":"Arch Neurol"},{"key":"6251_CR20","first-page":"346","volume":"53","author":"Y Ohashi","year":"2001","unstructured":"Ohashi Y, Tashiro K, Itoyama Y et al (2001) Study of functional rating scale for amyotrophic lateral sclerosis: revised ALSFRS (ALSFRS-R) Japanese version. No To Shinkei 53:346\u2013355","journal-title":"No To Shinkei"},{"issue":"Suppl 3","key":"6251_CR21","doi-asserted-by":"crossref","first-page":"III16","DOI":"10.1007\/BF03161085","volume":"246","author":"C Jenkinson","year":"1999","unstructured":"Jenkinson C, Fitzpatrick R, Brennan C, Bromberg M, Swash M (1999) Development and validation of a short measure of health status for individuals with amyotrophic lateral sclerosis\/motor neurone disease: the ALSAQ-40. J Neurol 246(Suppl 3):III16\u2013III21","journal-title":"J Neurol"},{"key":"6251_CR22","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/jnnp.70.1.70","volume":"70","author":"C Jenkinson","year":"2001","unstructured":"Jenkinson C, Fitzpatrick R (2001) Reduced item set for the amyotrophic lateral sclerosis assessment questionnaire: development and validation of the ALSAQ-5. J Neurol Neurosurg Psychiatry 70:70\u201373","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"6251_CR23","first-page":"483","volume":"56","author":"T Yamaguchi","year":"2004","unstructured":"Yamaguchi T, Ohbu S, Saito M et al (2004) Validity and clinical applicability of the Japanese version of amyotrophic lateral sclerosis\u2013assessment questionnaire 40 (ALSAQ-40). No To Shinkei 56:483\u2013494","journal-title":"No To Shinkei"},{"key":"6251_CR24","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1212\/WNL.33.10.1316","volume":"33","author":"UA Besinger","year":"1983","unstructured":"Besinger UA, Toyka KV, H\u00f6mberg M et al (1983) Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology 33:1316\u20131321","journal-title":"Neurology"},{"key":"6251_CR25","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/mus.21077","volume":"38","author":"Y Takeuchi","year":"2008","unstructured":"Takeuchi Y, Katsuno M, Banno H et al (2008) Walking capacity evaluated by the 6-minute walk test in spinal and bulbar muscular atrophy. Muscle Nerve 38:964\u2013971","journal-title":"Muscle Nerve"},{"key":"6251_CR26","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1212\/WNL.0b013e3181d3e308","volume":"74","author":"J Montes","year":"2010","unstructured":"Montes J, McDermott MP, Martens WB et al (2010) Six-minute walk test demonstrates motor fatigue in spinal muscular atrophy. Neurology 74:833\u2013838","journal-title":"Neurology"},{"key":"6251_CR27","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1080\/09638280500164479","volume":"27","author":"S Savci","year":"2005","unstructured":"Savci S, Inal-Ince D, Arikan H et al (2005) Six-minute walk distance as a measure of functional exercise capacity in multiple sclerosis. Disabil Rehabil 27:1365\u20131371","journal-title":"Disabil Rehabil"},{"key":"6251_CR28","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/ana.410320517","volume":"32","author":"M Doyu","year":"1992","unstructured":"Doyu M, Sobue G, Mukai E, Kachi T, Yasuda T, Mitsuma T, Takahashi A (1992) Severity of X-linked recessive bulbospinal neuronopathy correlates with size of the tandem CAG repeat in androgen receptor gene. Ann Neurol 32:707\u2013710","journal-title":"Ann Neurol"},{"key":"6251_CR29","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1212\/WNL.0b013e318199049e","volume":"72","author":"O Rascol","year":"2009","unstructured":"Rascol O (2009) \u201cDisease-modification\u201d trials in Parkinson disease: target populations, endpoints and study design. Neurology 72:S51\u2013S58","journal-title":"Neurology"},{"key":"6251_CR30","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3109\/17482968.2010.498521","volume":"11","author":"M Carvalho de","year":"2010","unstructured":"de Carvalho M, Pinto S, Costa J, Evangelista T, Ohana B, Pinto A (2010) A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 11:456\u2013460","journal-title":"Amyotroph Lateral Scler"},{"key":"6251_CR31","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3109\/17482960903307805","volume":"11","author":"RM Pascuzzi","year":"2010","unstructured":"Pascuzzi RM, Shefner J, Chappell AS et al (2010) A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 11:266\u2013271","journal-title":"Amyotroph Lateral Scler"},{"key":"6251_CR32","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1474-4422(07)70270-3","volume":"6","author":"PH Gordon","year":"2007","unstructured":"Gordon PH, Moore DH, Miller RG et al (2007) Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 6:1045\u20131053","journal-title":"Lancet Neurol"},{"key":"6251_CR33","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0079-6123(09)17520-9","volume":"175","author":"A Pollo","year":"2009","unstructured":"Pollo A, Benedetti F (2009) The placebo response: neurobiological and clinical issues of neurological relevance. Prog Brain Res 175:283\u2013294","journal-title":"Prog Brain Res"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-011-6251-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-011-6251-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-011-6251-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T15:22:55Z","timestamp":1559056975000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-011-6251-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,28]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["6251"],"URL":"https:\/\/doi.org\/10.1007\/s00415-011-6251-2","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,28]]}}}